Last reviewed · How we verify
bOPV 1,3
bOPV 1,3 is a bivalent oral polio vaccine containing live attenuated poliovirus types 1 and 3 that induces mucosal and systemic immunity against poliomyelitis.
bOPV 1,3 is a bivalent oral polio vaccine containing live attenuated poliovirus types 1 and 3 that induces mucosal and systemic immunity against poliomyelitis. Used for Poliomyelitis prevention in infants and children.
At a glance
| Generic name | bOPV 1,3 |
|---|---|
| Also known as | Bivalent Oral Polio Vaccine |
| Sponsor | Institute of Medical Biology, Chinese Academy of Medical Sciences |
| Drug class | Live attenuated viral vaccine |
| Target | Poliovirus types 1 and 3 |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine delivers live attenuated (weakened) poliovirus serotypes 1 and 3 orally, stimulating both intestinal mucosal immunity (IgA) and systemic humoral immunity (IgG) against these poliovirus types. This approach provides protection against wild-type poliovirus infection while minimizing the risk associated with monovalent formulations by covering two serotypes simultaneously.
Approved indications
- Poliomyelitis prevention in infants and children
Common side effects
- Vaccine-derived poliovirus (VDPV) shedding
- Mild gastrointestinal symptoms
- Fever
Key clinical trials
- Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (PHASE3)
- Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines (PHASE1, PHASE2)
- Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants (PHASE3)
- A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants (PHASE3)
- Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV) (PHASE4)
- Immunogenicity nOPV2 With and Without bOPV (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine (PHASE2)
- Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bOPV 1,3 CI brief — competitive landscape report
- bOPV 1,3 updates RSS · CI watch RSS
- Institute of Medical Biology, Chinese Academy of Medical Sciences portfolio CI